D.E. Shaw & Co
EFTR

D.E. Shaw & Co’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

D.E. Shaw & Co’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,674
Closed -$1.65M – 5318
2021
Q2 		$1.65M Buy
+6,674
New +$1.64M ﹤0.01% 3134

Other funds holding EFTR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

D.E. Shaw & Co's EFTR Position: Q3 2021 in Review

D.E. Shaw & Co sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2021, closing a stake of 6,674 shares — an estimated $1.65M sold.

D.E. Shaw & Co first reported a position in EFTR in Q2 2021 and held it in 1 quarter. The position peaked at $1.65M in Q2 2021. 12 funds tracked by Wall St. Rank hold EFTR as of Q3 2021.

  • D.E. Shaw & Co reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 6,674 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.65M.
  • D.E. Shaw & Co first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • D.E. Shaw & Co's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $1.65M in Q2 2021.
  • 12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.